Advertisement
Letter| Volume 48, ISSUE 5, P415, November 1979

Letter to the editor

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Harrison G.G.
        Control of the Malignant Hyperpyrexic Syndrome in MSH Swine by Dantrolene Sodium.
        Br. J. Anaesth. 1975; 47: 62
        • Pandit S.K.
        • et al.
        Orally Administered Dantrolene for Prophylaxis of Malignant Hyperthermia.
        Anesthesiology. 1979; 50: 156
        • Faust D.K.
        • et al.
        Management of Suspected Malignant Hyperexia in an Infant.
        Anesth. Analg. 1979; 58: 33
      1. Gallagher, D. M., and Hyer, R. L.: Dantrolene Administration in a Malignant Hyperthermia Susceptible Human. (Submitted for publication.)

        • Gronert G.A.
        • et al.
        Dantrolene in Porcine Malignant Hyperthermia.
        Anesthesiology. 1976; 44: 488
        • Anderson I.L.
        • Jones E.W.
        Porcine Malignant Hyperthermia.
        Anesthesiology. 1976; 44: 57
        • Nelson T.E.
        • Flewellen E.H.
        Rationale for Dantrolene vs. Procainamide for Treament of Malignant Hyperthermia.
        Anesthesiology. 1979; 50: 118
        • Dykes M.H.M.
        Evaluation of a Muscle Relaxant: Dantrolene Sodium (Dantrium).
        J. Am. Med. Assoc. 1975; 231: 862